cartilage for the treatment of focal traumatic lesions in the knee in a phase I clinical trial (Mumme et 36 al., 2016) , and a phase II clinical trial is ongoing to investigate efficacy. Briefly, autologous nasal 37 chondrocytes are expanded in vitro before seeding onto a collagen I/III scaffold and cultured in 38 chondrogenic conditions to produce a mature, hyaline-like cartilage graft that is then implanted into 39 the knee cartilage defect of the same patient. 40
The starting material for this approach is a biopsy from the native nasal septum cartilage, which, like 41 articular cartilage, is a hyaline cartilage (Al Dayeh et al., 2013) composed predominantly of water, type 42 II collagen, glycosaminoglycan (GAG) containing proteoglycans, and the one cell type, chondrocytes 43 (Buckwalter et al., 1998) . Mucoperichondrium is the tissue that overlays nasal cartilage; it consists of 44 several layers, including mucosa, lamina propria, and perichondrium, the tissue directly adjacent to the 45 cartilage that is tightly attached and cannot be easily distinguished (Aksoy et al., 2012). Currently, 46 nasal septal cartilage and mucoperichondrium are separated by pulling them apart with forceps and are 47 identified based on their physical characteristics. Due to donor-related and operator-related variability, 48 the resulting biopsy may not be completely pure after cleaning, with some overlaying tissue remaining 49 attached to the cartilage. 50
When working with intrinsically variable donor-derived human materials, such as tissues and cells, 51 establishing the quality and consistency of the starting material is key to ensuring reproducibly high 52 quality engineered products, not least to avoid the consequences of cell misidentification (Hyun-woo, Moreover, the impact of possibly contaminating cells on nasal chondrocyte-based engineered cartilage 59
has not been investigated. 60 Engineered products treat diseases or damage through repairing, replacing, or regenerating tissues or 61 organs (Detela et al., 2019) . A potency assay must be developed based on the mode of action of the 62 tissue engineered product (CHMP 2008)-in our case, the filling of cartilage defects with healthy, 63 hyaline-like tissue-which is ideally correlated to the efficacy, leading to consistent quality of the tissue 64 engineered product and good clinical outcome (Bravery et al., 2013) . 65
In this study, we first investigate which cell types are potentially contaminating in human nasal septum 66 cartilage biopsies and their impact on the quality of engineered cartilage. We then investigated whether 67 gene expression analysis could discriminate the contaminant cells found in nasal septal biopsies for the 68 development of a characterization panel for identity and purity quality controls. To assess potency, we 69 compared the gene expression of nasal septum biopsy-derived cells to their ability to produce 70 cartilaginous tissue. Finally, we propose how these purity and potency assays could be implemented 71 in a Good Manufacturing Practice (GMP) compliant process for the translation of our regenerative 72 therapy product. 73 containing 4.5 mg/mL D-glucose and 0.1 mM nonessential amino acids, 10% fetal bovine serum (FBS), 85 1 mM sodium pyruvate, 100 mM HEPES buffer, 100 U/mL penicillin, 100 μg/mL streptomycin, and 86 0.29 mg/mL L-glutamine (all from Invitrogen), supplemented with 1 ng/mL transforming growth 87 factor beta-1 (TGF-β1) and 5 ng/mL fibroblast growth factor-2 (FGF-2) (both from R&D Systems) at 88 37°C and 5% CO2 in a humidified incubator (Thermo Scientific Heraeus) as previously described 89 (Jakob et al., 2003) . When approaching 80% confluence, cells were detached using 0.05% trypsin-90 EDTA (Invitrogen) and re-plated. 91 PC tissue samples were cut in small pieces and put on the bottom of plastic culture dishes to isolate 92 adherent cells that migrated out of the tissue for one week in complete medium. Cells were then 93 detached using 0.05% trypsin-EDTA and further cultured until confluence in the same conditions as 94 nasal chondrocytes. 95
Specific ratios of NC to PC cells were combined at passage two to generate mixed populations of 96 known purity of 100%, 90%, 80%, 70%, 60%, and 0% NC. 97
For all other biopsies, in case perichondrium was present, half of the sample was dissected removing 98 all perichondrium to obtain a pure nasal cartilage sample (NC), while the overlaying perichondrium 99 remained intact on the other half (NC+PC samples). Cells were isolated from each tissue sample by 100 enzymatic digestion and expanded in complete medium supplemented with TGF-β1 and FGF-2 up to 101 2 passages as described above for nasal chondrocytes. 102
Chondrogenic redifferentiation 103

Micromass pellets 104
Cells expanded until passage two were redifferentiated by culturing as 3D micromass pellets, as 105 previously described (Asnaghi et al., 2018). 3D micromass pellets were formed by centrifuging 5x10 5 106 cells at 300 x g in 1.5 mL conical tubes (Sarstedt) and cultured for two weeks in chondrogenic serum-107 free medium consisting of DMEM containing 1 mM sodium pyruvate, 100 mM HEPES buffer, 100 108 U/mL penicillin, 100 μg/mL streptomycin, 0.29 g/mL L-glutamine, 1.25 mg/mL human serum albumin 109 (CSL Behring), and 100nM dexamethasone (Sigma, Switzerland), supplemented with 10 ng/mL TGF-110 β1 (R&D), ITS+1 (10 µg/mL insulin, 5.5 µg/mL transferrin, 5 ng/mL selenium; Gibco), 100 µM 111 ascorbic acid 2-phosphate (Sigma), and 4.7 µg/mL linoleic acid (Sigma expression analysis was performed as previously described (Martin et al., 2001 ). Reverse transcriptioninto cDNA was done from 3 μg of RNA by using 500 μg/mL random hexamers (Promega, Switzerland) 156 and 0. 
Biochemical quantification of GAG and DNA 165
Samples of engineered cartilage and micromass pellets were digested with proteinase K (1 mg/mL 166 proteinase K in 50 mM Tris with 1 mM EDTA, 1 mM iodoacetamide, and 10 mg/mL pepstatin A). The 167 GAG content was determined by spectrophotometry using Dimethylmethylene Blue (Sigma-Aldrich 168 341088) as previously described (Barbosa et al., 2003) . DNA content was measured using the CyQuant 169 cell proliferation assay kit (Invitrogen). 170
Modeling 171
The generalized linear modeling (glm) function in R was used to build all the models. A logistic 172 regression model was used to predict purity, where the response is a continuous probability between 0 173 (pure perichondrium) and 1 (pure cartilage) with samples from four donors and 48 independent 174 experiments of known purities. For the logistic regression models, the 
Characterization of perichondrial cells 223
The samples we classify as pure nasal cartilage (NC) and perichondrium (PC) are the tissues after 224 separation using the aforementioned technique. Visually, under macroscopic observation during 225 expansion in cell culture dishes, NC and PC cells are not distinguishable, both having the same 226 characteristic fibroblastic-like cell morphology. The proliferation rates of the two cell types were 227 measured and found to be about equal (Fig 2A) . To compare the chondrogenic capacity of NC and PC 228 cells, we engineered pellets and found that NCs could reproducibly produce GAG and collagen II while 229
PCs could not and predominantly produced type I collagen, as seen by histological analyses and 230 biochemical quantification (Fig 2B,C) . 231
Identity assay 232
We sought to distinguish the cells from these two tissues based on their gene expression profiles. NC 233 cells expressed significantly higher levels of type II collagen and relative ratios of collagen II:I, 234 aggrecan:versican and, at passage two, HAPLN1:MFAP5; whereas PC cells expressed significantly 235
higher levels of versican, MFAP5, and nestin (Fig 3) . Expanded cells were then cultured as 3D 236 micromass pellets in chondrogenic conditions for two more weeks. NC cells from engineered pellets 237 expressed significantly more collagen II and higher ratios of collagen II:I, aggrecan:versican, and 238 HAPLN1:MFAP5, and PC cells expressed significantly higher levels of versican and MFAP5 (Fig S1) . 239
In summary, these results demonstrate that nasal chondrocytes and perichondrial cells have statistically 240 significant differential expression of cartilage-related genes both during expansion and after pellet 241 culture. 242
Purity assay 243
The only method currently available to assess the purity of the starting native cartilage biopsy is by 244 manually counting the number of cells in each type of tissue in a histological image (Fig S2) . This 245 method suffers from limitations due to histological artifacts, unclear distinction between tissue types, 246 its semi-quantitative and destructive nature, and the fact that a histological section may not be 247 representative of the whole tissue. Here we assessed if the purity of a mixed cell population could also 248 be estimated based on gene expression analysis. 249
Spearman correlation coefficients (ρ) of the gene expression of cells at passage two that we combined 250 at specific ratios of NC and PC cells revealed statistically significant trends across donors. Due to high 251 donor-to-donor variability, the correlations between cell population purity and gene expression were 252 higher per donor per gene than across donors. The highest correlation was found for the relative 253 expression of aggrecan:versican (ρ = 0.69), where the ratio was higher in purer populations containing 254 more NCs; per donor the correlations were even stronger (ρ = 0.61-0.98) (Fig S3A) . 255
In general, more significant differences in gene expression in individual genes and cell purity were 256 seen at passage two compared to the pelleted cells' gene expression (Fig S3B) . Therefore, we focused 257 on passage two for the subsequent purity model. 258 The purity predicted by the model was plotted against the known purity and the resulting R 2 value of 269 the observed and predicted values was 0.79 ( Fig 4B) . 270
Potency assay 271
We investigated whether predictive gene expression markers can be used to estimate the capacity of 272 the cells to form engineered cartilage. The final cartilage quality is currently assessed using the GAG content as well as the histological MBS score of the chondrogenic pellets were positively 276 correlated to the cartilage identity gene expression markers and negatively correlated to the 277 perichondrial identity markers (Fig S4) . The interrelationship of potency and purity is visualized in the 278 top left corner of the correlation plot, which shows that purity (NC%), GAG, GAG/DNA, and MBS 279 are highly correlated (Fig 5) . 280 More significant gene expression trends were seen when analyzing the cells at passage two compared 281 to after engineered pellet culture, so we developed a potency assay for this time point. 282
In order to develop a potency assay that could predict the amount of GAG in the final engineered 283 cartilage based on the gene expression of the starting cell population, we trained a generalized linear 284 model with a log-link and gamma distribution. Figure 6A ). The equation of the potency assay to predict the amount of 290 GAG produced via the gene expression of passage two cells (Equation 2), where the ∆Ct values of the 291 genes should be entered, was generated using both the test and training data together, to report the most 292 accurate coefficient estimates possible. and immunohistochemical analysis of collagen types II and I (S5). We confirmed the negative effect 308 of perichondrial cells on the engineered cartilage not only in pellet culture, but also when produced 309 according to the clinical trial protocol where cells are seeded onto a collagen I/III scaffold (Fig S6) . 310
A threshold of acceptable purity needs to be set to guarantee the quality of the final product. Known 311 quantities of NC and PC cells were mixed together and chondrogenic pellets were produced. 312
Histological scoring was then used to set acceptable limits of PC cell contamination so that the quality 313 of the final product would still meet the clinical trial release criteria (MBS ≥ 3). Due to donor-to-donor 314 variability, potential cross-contamination from the mechanical tissue separation method, and 315 considering the limitations of histological analysis, we show that some donors could still produce 316 cartilage matrix of sufficient quality with up to 40% PC contamination, while the less potent donors 317 could produce cartilage matrix with a PC contamination of up to 30% PC cells (Fig 7A) . 318
Using the purity and potency assays we developed, the quality was estimated based on the passage two 319 gene expression of cell populations for clinical trial samples and for heterogeneous biopsies collected 320 from patients that underwent plastic surgeries with variable amounts of overlaying perichondrium. The 321 predicted histological score results closely matched the actual values, and the quantified amounts of 322 GAG could be estimated well, predicting if cells would produce high or low amounts of GAG (Fig  323  7B) . The clinical trial starting materials were assessed to be pure and the potency assays predicted good 324 chondrogenic capacity which was confirmed by the high quality of the engineered cartilage. The more 325 heterogeneous cartilage samples from plastic surgery procedures had more variable results. The purity 326 assay predicted the worst sample to have a purity of 20%, many samples to be 99% pure, and the mean 327 purity of mixed samples to be 75% (Fig 7C) . Consistent with the established purity threshold, cells that 328 were predicted to be >70% pure were all able to produce cartilaginous tissues that passed the 329 histological score release criteria. The sample with a predicted purity of 20%, on the other hand, 330 produced a pellet that failed the release criteria (histological score = 2.3). 331
Discussion 332
In this study, we established novel, in-process controls to ensure the quality and standardization of 333 nasal chondrocyte-based engineered cartilage grafts. Histological analysis revealed that nasal septal 334 cartilage may be harvested with some adjacent tissue, and that there may still be fragments of 335 perichondrial tissue overlaying the cartilage even after a trained operator further separates the tissues. 336
Although some researchers claim that perichondrial cells from other cartilage sources have 337 chondrogenic potential (Hellingman et al., 2011), we discovered that unlike chondrocytes, nasal septal 338 perichondrial cells do not have the capacity to form GAG-and collagen type II-rich engineered tissues. 339
We found that increasing amounts of perichondrium in the starting material profoundly decreases the 340 quality of engineered cartilage, as seen by less GAG and collagen II production during chondrogenic 341 culture. Therefore, minimal contamination of perichondrial cells must be ensured. The NC identity 342 marker we found is collagen II, and the PC identity markers were, versican, MFAP5, and nestin. To 343 quantitatively determine the percentage of contaminating cells in a population, we developed a model 344 that correlates the expression of multiple gene expression markers to the purity of a cell population. 345
Similarly, to predict the chondrogenic capacity of a cell population, we built models to estimate GAG 346 production and the final histological MBS score in engineered cartilage. Finally, we discuss how such 347 quality controls could be implemented during the production of cell or tissue therapies. 348
In practice, polymerase chain reaction (PCR) instrumentation is ubiquitous, so a gene expression-based 349 quality control could be easily implemented. at certain time points than others (Tekari et al., 2014) . From a practical perspective, an earlier quality 358 control would save costs, because the quality of the cells could be established before an expensive 359 production is undertaken. However, after one or two weeks of cell expansion, there are many more 360 cells and an aliquot can be taken without depleting the whole cell population and the gene expression 361
analysis of an aliquot of a cell suspension provides a broad readout of the total cellular material. 362
Obtaining cells before they are embedded in the scaffold would allow to perform the analysis 363 nondestructively. Importantly, the biomarkers we investigated had the most distinct expression levels 364 after the expansion phase. Consequently, we propose that our gene expression-based assays should be 365 implemented on expanded passage two cells. 366
Generalized linear models for the development of gene expression-based quality controls for 367 regenerative medicine is a natural extension of their use in biomarker-based disease diagnosis (Hosmer  368  et 2014), which, like nasal cartilage, is derived from cranial neural-crest cells (Chai et al., 2000) . The 389 predictive ability of these models are significant especially when considering that only ∼30-40% of 390 the variance in protein abundance is explained by mRNA levels (Vogel et al., 2012 ). The selection of 391 different genes for each potency assay may be due to the fact that they assess quality in slightly different 392 ways; the histological score includes information not only of the GAG content, but also about the 393 morphology of the cells. 394
We observed that all pellets that contained at least 70% NC cells pass the clinical trial release criteria, 395
i.e., histological score ≥ 3, but more contamination could also lead to good results in some cases. To 396 implement the purity assay, we propose a conservative three-category rating scale for the predicted 397 purity (NC%), i.e., if cells are estimated to be more than 70% pure, they are labeled as pure, less than 398 50% pure, they are labeled as fail, otherwise the estimation is labeled as uncertain. We propose to 399 introduce this uncertain region for the time being until further data can be collected and the estimates 400 can be made more precise. In practice, we would recommend that starting cell populations labeled as 401 pure or uncertain should continue in the production process, however, if the cells fail the purity test, 402 the costly production should be halted. Cartilage engineered from cells of uncertain purity would 403 nevertheless need to pass the release criteria (such as the histological score-based release criterial), 404 ensuring the quality of the product. 405
The selected genes and coefficient estimates for the models will have to be updated as more data are 406 obtained, and the in-process controls will have to be validated to meet GMP standards. Moreover, the 407 definition of a high quality graft may need to be revised as more long-term clinical outcome data are 408 collected. 409
In conclusion, we have put forward gene expression-based assays for identity, purity, and potency to 410 help ensure the safe and effective clinical use of nasal chondrocyte-derived engineered cartilage. Moregenerally, we provide an example of the development and implementation of purity and potency assays 412 based on relatively simple qPCR assays, stepwise selection of the most significant genes, and predictive 413 in silico models. This approach could be relevant for the development of quality controls for other 414 products in the emerging field of regenerative medicine, one of the biggest challenges for advanced 415 therapy medicinal products to overcome for clinical translation. 416 
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